Page 5 - Mark Mintun News Today

Another experimental Alzheimer’s drug can modestly slow patients’ inevitable worsening — by about four to seven months, researchers reported Monday.

But the drug, an antibody that attacks the sticky protein amyloid, does not work as well in people with more advanced disease. But the drug, an antibody that attacks the sticky protein amyloid, does not work as well in people with more advanced disease.

WASHINGTON (AP) — Another experimental Alzheimer’s drug can modestly slow patients’ inevitable worsening — by about four to seven months, researchers reported Monday. Eli Lilly and Co. is seeking Food and Drug Administration approval of donanemab. If cleared, it would be only the second Alzheimer’s treatment convincingly shown to delay the mind-robbing disease — after […]

Another experimental Alzheimer’s drug can modestly slow patients’ inevitable worsening — by about four to seven months, researchers reported Monday.

In a phase 3 trial, the monoclonal antibody donanemab slowed clinical and functional decline by 35% for patients with early Alzheimers disease. However, the drug was not without safety issues.

Another experimental Alzheimer’s drug can modestly slow patients’ inevitable worsening — by about four to seven months, researchers reported Monday.

Another experimental Alzheimers drug can modestly slow patients inevitable worsening — by about four to seven months, researchers reported Monday.

MONDAY, July 17, 2023 (HealthDay News) -- Another experimental drug meant to slow the damage of Alzheimer’s appears poised to join a growing arsenal of new treatments for this memory-robbing

Another experimental drug meant to slow the damage of Alzheimer's appears poised to join a growing arsenal of new treatments for this memory-robbing disease.

Patients given monthly infusions of Eli Lilly and Co.’s donanemab declined about four to seven months more slowly than those given dummy infusions in a large study